The global scleroderma therapeutics market is projected to grow at a considerable CAGR of around 4% during the forecast period (2020-2026). Scleroderma is a chronic autoimmune disease that results in chronic hardening and tightening of the skin and connective tissues. This disease is more common in females compared to males and is likely to develop at the age of 30-50 years. The rising female geriatric population along with the rising prevalence of scleroderma therapeutics to be a key contributor to the growth of the market across the globe.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/scleroderma-therapeutics-market
The advent of new first-in-class therapeutic that are currently undergoing clinical development and trial therapeutics. For instance, in March 2020, Emerald Health Pharmaceuticals Inc., a clinical-stage biotechnology company that develops drugs and medicines based on cannabinoid science, has initiated a Phase 2a international clinical study for the treatment of patients with systemic sclerosis (SSc), a severely debilitating and life-threatening form of scleroderma.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/scleroderma-therapeutics-market
Furthermore, the presence of increasing approvals for the existing treatment options to further anticipated boosting the market growth of scleroderma therapeutics across the globe. The ongoing R&D by the major market players to find out new novel therapies for the treatment of the disease is anticipated to offer huge opportunities to the growth of the global market. However, stringent rules and regulations, high costs associated with the therapies, and the adverse effects of drugs are the key factors that may restrain the growth of the global scleroderma therapeutics market.
Market Segmentation
Global Scleroderma Therapeutics Market by Disease Type
- Systemic Scleroderma
- Localized Scleroderma
Global Scleroderma Therapeutics Market by Drug Type
- Phosphodiesterase 5 inhibitors – PHA
- Prostacyclin Analogues
- Immunosuppressors
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
